Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 8/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30900092 | 1.00 | CYP2A13 (0.71) | CYP2A13MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL520610 | 0.87 | CYP2A13 (0.61) | CYP2A13MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2208032 | 0.85 | ACHE (0.60) | CYP2A13MAPTSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL6340603 | 0.83 | CYP2C9 (0.56) | CYP2A13MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3859176 | 0.83 | ACHE (0.58) | CYP2A13MAPTSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL4109682 | 0.83 | CYP2A13 (1.00) | CYP2A13MAPTSMN1; SMN2ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL6340504 | 0.82 | CYP2C9 (0.54) | CYP2A13MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL4935736 | 0.81 | MAPT (0.57) | CYP2A13MAPTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL4262170 | 0.81 | CYP2A13 (0.61) | CYP2A13MAPTGAATDP1CYP2C9 | |
| SCHEMBL591420 | 0.81 | ALDH1A1 (0.64) | CYP2A13MAPTSMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | claimed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | claimed |
| EP-3740484-B1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-03-23 | — | — | US | disclosed |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-03-11 | — | — | US | disclosed |
| EP-3740484-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA HOLDINGS PTY LTD (AU) | 2020-11-25 | — | — | EP | disclosed |
| EP-3205645-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-9957251-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-3205645-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-16 | — | — | EP | disclosed |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-16 | — | — | US | disclosed |
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | CYP2A13 4138/4885MAPT 1542/4885SMN1; SMN2 2982/4885 |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | CDK8, CDK18, CDK9 | CYP2A13 4138/4885MAPT 1542/4885SMN1; SMN2 2982/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | CYP2A13 666/4885MAPT 1795/4885SMN1; SMN2 4156/4885 |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | CYP2A13 4138/4885MAPT 1542/4885SMN1; SMN2 2982/4885 |
| US-20170044132-A1 | HETEROCYCLIC COMPOUND | CDK19, CDK9, CDK8 | CYP2A13 3740/4885MAPT 2330/4885SMN1; SMN2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.